Regeneron director proposes $360K share sale
The notice also lists two earlier 400-share sales by Guarini during the preceding three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. (REGN) director Kathryn Guarini submitted notice of a proposed sale of 400 common shares, with an aggregate market value of $360,000. The notice lists an approximate sale date of October 30, 2026, through UBS Financial Services, Inc., on Nasdaq. The shares are listed as acquired through exercise of a stock option from the issuer, with cash payment. During the prior three months, Guarini reported sales of 400 shares on August 10, 2026, for $320,000, and 400 shares on September 2, 2026, for $340,000.
Key Figures
Key Terms
Rule 144 regulatory
Exercise of stock option financial
attorney-in-fact technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.